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Abstract
Background: Detection of acute HIV infection (AHI) with pooled nucleic acid amplification testing (NAAT) following HIV
testing is feasible. However, cost-effectiveness analyses to guide policy around AHI screening are lacking; particularly after
more sensitive third-generation antibody screening and rapid testing.
Methods and Findings: We conducted a cost-effectiveness analysis of pooled NAAT screening that assessed the prevention
benefits of identification and notification of persons with AHI and cases averted compared with repeat antibody testing at
different intervals. Effectiveness data were derived from a Centers for Disease Control and Prevention AHI study conducted
in three settings: municipal sexually transmitted disease (STD) clinics, a community clinic serving a population of men who
have sex with men, and HIV counseling and testing sites. Our analysis included a micro-costing study of NAAT and a
mathematical model of HIV transmission. Cost-effectiveness ratios are reported as costs per quality-adjusted life year (QALY)
gained in US dollars from the societal perspective. Sensitivity analyses were conducted on key variables, including AHI
positivity rates, antibody testing frequency, symptomatic detection of AHI, and costs. Pooled NAAT for AHI screening
following annual antibody testing had cost-effectiveness ratios exceeding US$200,000 per QALY gained for the municipal
STD clinics and HIV counseling and testing sites and was cost saving for the community clinic. Cost-effectiveness ratios
increased substantially if the antibody testing interval decreased to every 6 months and decreased to cost-saving if the
testing interval increased to every 5 years. NAAT was cost saving in the community clinic in all situations. Results were
particularly sensitive to AHI screening yield.
Conclusions: Pooled NAAT screening for AHI following negative third-generation antibody or rapid tests is not cost-
effective at recommended antibody testing intervals for high-risk persons except in very high-incidence settings.
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Acute HIV infection (AHI) is the stage of disease immediately
after HIV acquisition and before HIV antibodies are detectable,
when viral replication and shedding peak [1]. Because persons
with AHI are highly infectious, are probably unaware of their
status, and may still be engaging in high-risk behaviors, identifying
persons with AHI offers an important opportunity for HIV
prevention. However, the diagnosis of AHI is challenging because
it involves expensive laboratory-based nucleic acid testing and
modification of current HIV screening algorithms.
To screen for AHI, a nucleic acid amplification test (NAAT)
that detects the presence of HIV RNA during the window period
before antibodies are detectable is performed on seronegative
specimens. Pooled NAAT, in which specimens are pooled before
testing, is employed because individual NAAT is prohibitively
expensive [2]. Pooled NAAT is routinely used to detect AHI in
blood donors [3], and several studies have shown that pooled
NAAT after HIV antibody screening is feasible in clinic settings
[4–9]. However, these studies screened for HIV antibodies with
first- or second-generation enzyme immunoassays (EIAs) that
are less sensitive for early infection because they detect only
immunoglobulin G (IgG). Third-generation EIAs detect IgG and
also immunoglobulin M (IgM), the first class of antibody to appear
after infection, and thus detect HIV infection earlier than first- or
second-generation EIAs, resulting in fewer antibody-negative cases
to be detected by NAAT [2,10]. It is also important to evaluate the
use of rapid testing in combination with pooled NAAT, given that
rapid tests, though less sensitive than third-generation laboratory-
based EIAs during early infection, are increasingly being used for
screening, as results are available the same day as testing, which
increases numbers of persons who learn their test results [10–12].
No study to date has evaluated the cost-effectiveness of con-
ducting pooled NAAT screening for AHI in clinic settings; and
cost-effectiveness data are needed to inform policy around AHI
screening including an evaluation of the relationship between cost-
effectiveness of AHI screening in settings with varying HIV
incidences [9,13,14]. We conducted a cost-effectiveness analysis of
pooled NAAT screening for AHI after antibody testing with both
third-generation EIAs and rapid tests in three settings.
Methods
Our analysis was conducted concurrently with the Centers for
Disease Control and Prevention (CDC) multisite AHI study that
used pooled NAAT screening for AHI detection in different
clinical settings [15]. We constructed an Excel-based model to
compare the cost and effectiveness of screening for AHI after HIV
antibody screening. Our analysis, which includes a micro-costing
study of NAAT testing and a cost-effectiveness model that
incorporates the benefits attributable to reduced HIV transmis-
sion, conforms to the reference case recommendations of Gold
[16]. All costs are reported in 2008 US dollars, future costs are
discounted at a 3% annual rate, and outcomes are expressed as
cost per quality-adjusted life year (QALY) gained because of cases
of HIV infection averted due to pooled NAAT screening. Our
incremental cost-effectiveness analysis compares pooled NAAT
screening for AHI with screening for HIV antibodies only.
We calculated the total number of persons identified with AHI
and the number of potential HIV transmissions averted due to
NAAT screening in three settings. We did not include benefits of
antiretroviral therapy (ART) to persons identified with AHI, given
inconclusive evidence for the effectiveness of ART during AHI.
We also assumed that most persons diagnosed with AHI would
start ART when their CD4 count declined below 350 cells/ml, and
this has been estimated to occur 6–8 y after infection [17–20].
QALYs and lifetime medical costs were calculated on the basis of
published estimates. We estimated the cost per QALY gained from
a societal perspective and the cost per specimen collected and case
of HIV identified and notified from the provider perspective.
Population, Setting, Design
Effectiveness data were obtained from the CDC AHI study that
conducted pooled NAAT after third-generation EIA (Genetic
Systems 1/2 +O, BioRad Laboratories) in Florida and both a first-
generation assay (Vironostika HIV-1 Microelisa, Biomerieux Inc)
and third-generation EIA in Los Angeles [15]. We compared the
cost and effectiveness of NAAT screening in three settings with
different rates of HIV positivity (defined as the number of positive
HIV tests/the number of persons tested during the CDC AHI study)
and AHI positivity (defined as the number of AHIs identified/the
number of persons screened with pooled NAAT during the CDC
AHI study): (1) HIV counseling and testing sites (HIV positivity,
1.2%; AHI positivity, 0.01%), (2) municipal sexually transmitted
disease (STD) clinics (HIV positivity, 1.0%; AHI positivity, 0.02% ),
and (3) a community clinic serving men who have sex with men
(MSM) in Los Angeles (California) (HIV positivity, 1.8%; AHI
positivity, 0.21%). We used data by Louie et al. [11] to approximate
the yield of NAAT after antibody testing with a rapid test (see Text
S1). Our analysis is based on pooled NAAT after antibody testing
with either a third-generation EIA or a rapid test.
NAAT Screening Protocol
Pools of 16 EIA-negative specimens were tested with NAAT
(Aptima HIV-1 RNA qualitative assay, Gen-Probe Inc). Pools with
positive results underwent resolution testing in which all specimens
were tested with NAAT individually to identify the positive
specimen(s) and, if repeatedly positive, additionally tested with
viral load quantification (Versant HIV-1 RNA-branched DNA
assay v. 3.0, Siemens Inc.). All persons with EIA-negative/RNA-
positive test results were considered presumptive cases of AHI.
Experienced disease intervention specialists (DIS) notified pre-
sumptive cases of their results and initiated follow-up confirmatory
testing with Western blot and partner services to identify
potentially infected partners [15].
NAAT Screening Program Costs: Micro-Costing Study
Program costs were calculated for the addition of pooled NAAT
to an existing HIV testing program. To derive labor costs, we
conducted time-motion studies in the laboratories that performed
NAAT, and the DIS maintained logs of the time, effort, and travel
required to notify newly identified AHI cases and conduct partner
services. We conducted a detailed valuation of the costs of NAAT,
including reagents, equipment, labor, consumables, quality
assurance procedures, and shipping costs (incurred because NAAT
is typically conducted at high-volume laboratories). Screening costs
were calculated as an average cost per specimen tested with
NAAT. Costs incurred after presumptive AHI was detected
included DIS labor and travel costs and laboratory costs for
confirmatory testing, based on the actual number of AHI cases
detected in each setting. Table 1 summarizes the cost data;
detailed information is provided in Text S1.
Identification of AHIs with NAAT
Outcome data on the number of AHI cases detected after
pooled NAAT in each setting, days to result notification, and
proportion receiving NAAT results were taken from the CDC
AHI study (Table 2).
Cost-Effectiveness of Pooled NAAT
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We created a mathematical model of HIV transmission from
persons with AHI to their partners, on the basis of the awareness
of HIV status, stage of disease (acute or nonacute), and behavior
(sexual activity or needle-sharing), which is described in detail in
Text S1. The model is largely based on the difference in HIV
transmissions rates by awareness of HIV serostatus, in which the
transmission rate for those unaware of their HIV status is
estimated to be 3.5 times that of persons who are aware of their
status [21,22]. The estimated proportions of HIV transmissions
from sexual activity and from needle-sharing were based on 2006
national HIV surveillance data [23]. To estimate the potential
prevention benefits of NAAT screening, we estimated transmis-
sions averted during the interval from the time a person with AHI
learned of their HIV infection until the time that person would
have learned of their infection after antibody testing, had NAAT
not been used. In the base case, we assumed this interval to be 1 y
on the basis of recommendations for annual retesting of persons at
high risk. We also used an interval of 6 mo on the basis of HIV
screening recommendations for MSM and 5 y as an upper bound
on the basis of background testing rates for other populations
[24,25]. In addition, we calculated outcomes for the community
clinic that serves a MSM population on the basis of the 3-mo
interval recommended for retesting after recent exposure [26]. To
estimate the duration of time that NAAT screening would confer
awareness of HIV infection compared with antibody screening
alone, we calculated the total number of days during acute and
nonacute phases of infection that an infected person was aware of
his/her infection. We then applied estimated transmission
probabilities for each phase to calculate the total number of
transmissions averted that were attributable to the NAAT
screening program. In sensitivity analysis, we estimated the impact
of AHI detection on the basis of symptoms by estimating the
proportion of AHI cases that are symptomatic, seek care, and are
correctly diagnosed, and removing those estimated symptomatic
cases from the AHI cases that could be identified through pooled
NAAT screening for AHI [27–29]. See Text S1 for details.
QALYs and Lifetime Medical Costs Attributable to Pooled
NAAT Screening for AHI
We estimated QALYs gained from transmissions averted for
each setting, antibody testing technology, and timeframe to HIV
diagnosis in the absence of pooled NAAT. The QALYs gained
were expressed as the difference in QALYs for a partner with and
without HIV infection. We used published HIV-related utility
weights to estimate QALYs, assuming uninfected persons had a
QALY of 1.0 [30]. We assumed 35 y to be the average age at
which the partner would have become infected, on the basis of
2006 HIV incidence data, and an additional life expectancy of 32
y for persons infected with HIV [20,23] and 44.6 y for those who
remain uninfected [31]. We used published estimated lifetime HIV
treatment costs that were discounted to the time of infection and
Table 1. Cost parameters: Expressed as cost per specimen tested unless otherwise noted.
Cost Parameter Base Case (Sensitivity Analysis) US$ Reference
NAAT laboratory costs CDC AHI micro-costing study (primary
data collection)
Laboratory labor costs initial run 0.73 ‘‘
Laboratory shipping labor costs 0.18 (0) ‘‘
Laboratory supervision labor costs 0.20 ‘‘
Quality assurance training labor cost for two participants 0.04 ‘‘
Reagent cost per test
a 40 (0–100) ‘‘
Consumables 1.21 ‘‘
Shipping variable material costs 0.39 (0) ‘‘
Dedicated laboratory space
b 0.35 ‘‘
Nonlaboratory costs ‘‘
Prepare specimens for shipping 0.10 (0) ‘‘
Shipping delivery costs 1.00 (0) ‘‘
NAAT-positive costs ‘‘
Resolution labor costs 4.75 ‘‘
Resolution reagent cost per test 40 (0) ‘‘
DIS labor costs to notify NAAT + and conduct partner services 66.39 ‘‘
DIS mileage
c 18.57 [44]
Other cost data:
Confirmatory testing (EIA and Western blot) 58.22
d [45]
False positive NAAT test costs 286.22
e [45,46]
Lifetime treatment cost of HIV/AIDS 355,867
d (177,933–533,800) [20]
aReagent costs per tests are based on a reagent rental contract and include reagents, equipment, and training.
bBased on 22 square meters of dedicated lab space at US$37.00 per 0.09 square meter, http://www.colliers.com/Corporate/MarketReports/UnitedStates/.
cBased on 51.07 km at US$0.585 per 1.6 km, http://www.irs.gov/newsroom/article/0,,id=184163,00.html.
dAdjusted to 2008 US dollars.
eIncludes, labor, shipping, reagent costs, EIA, and HIV-1 viral load quantification.
doi:10.1371/journal.pmed.1000342.t001
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of US$355,867 [20]. Cost-effectiveness estimates were calculated
by subtracting projected HIV treatment costs for HIV infections
averted from total AHI program costs and dividing by the QALYs
gained for each averted HIV infection.
Sensitivity Analysis
We conducted sensitivity analyses around multiple parameter
values including: transmission rates by awareness of HIV
serostatus, antibody testing frequency, reagent and equipment
costs, shipping costs, receipt of NAAT results, and symptomatic
identification of AHI. We also conducted a threshold analysis on
AHI positivity rate to determine the AHI positivity at which AHI
screening with NAAT becomes cost-effective after third-genera-
tion EIA and rapid testing. Our sensitivity analysis was centered
on the municipal STD clinic setting because STD clinics have
been suggested as places to conduct AHI screening [9,32]. We also
conducted the sensitivity analysis on symptomatic detection of
AHI on the community clinic that serves MSM because it is the
setting in which NAAT is most likely to be cost-effective.
Results
Total program costs for NAAT screening after testing using a
third-generation EIA during the 22-mo study period were
approximately US$458,200 for the counseling and testing sites
(54,187 specimens), US$76,900 for the community clinic (5,574
specimens), and US$349,900 for the municipal STD clinics
(30,973 specimens) (Table 3). Program costs per specimen tested
ranged from US$8.46–US$14.14 in the three settings. The
calculated program costs per person identified with and notified
of AHI were approximately US$90,000 after screening with a
third-generation EIA and US$50,000 after screening with a rapid
test for both the counseling and testing sites and municipal STD
clinics, and US$7,900 and US$3,800, respectively, for the
community clinic.
Table 2. Key effectiveness parameters.
Effectiveness Parameter Base Case (Sensitivity Analysis) Source
AHI positivity; n AHIs using third-generation EIA:
HIV counseling and testing sites 0.01%, 7 CDC AHI study
Municipal STD clinic 0.02%, 5 CDC AHI study
Community clinic 0.21%, 12 CDC AHI study
AHI positivity; n AHIs w/rapid testing:
HIV counseling and testing sites 0.02%, 8.58 Calculated from CDC AHI
study [11]
Municipal STD clinic 0.03%, 6.86 Calculated from CDC AHI
study [11]
Community clinic 0.44%, 20.58 Calculated from CDC AHI
study [11]
Percent received NAAT results:
HIV counseling and testing sites 71% CDC AHI study
Municipal STD clinic 78% (50%–100%) CDC AHI study
Community clinic 81% CDC AHI study
Mean n days after infection to notification of NAAT results:
Third-generation EIA 32 Calculated
a
Rapid testing 48 Calculated
a
Median n days to notification of +NAAT:
HIV counseling and testing sites 15.5 CDC AHI study
Municipal STD clinic 15.5 (7–22) CDC AHI study
Community clinic 10 CDC AHI study
Transmission rate ratio from persons unaware to aware of HIV serostatus 3.5 (2.6–4.34) [21]
Transmission variables:
Sexual acute aware daily transmission 0.0005 (0.00095) Calculated from [21,47]
Sexual acute unaware daily transmission 0.00195 (0.3306) [47]
Sexual nonacute aware annual transmission 0.0253 (2.9) [47]
Sexual nonacute unaware annual transmission 0.0877 (10.1) [47]
IDU acute aware daily transmission 0.0028 Calculated from [38,48]
IDU acute unaware daily transmission 0.0036 Calculated from [38,48]
IDU nonacute aware annual transmission 0.126 [38,48]
IDU nonacute unaware annual transmission 0.165 [38,48]
IDU, injection drug user.
aSee Text S1.
doi:10.1371/journal.pmed.1000342.t002
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Generation EIA
The addition of pooled NAAT after a negative third-generation
EIA to detect AHI had a cost-effectiveness ratio of US$372,300
per QALY gained for the counseling and testing sites,
US$484,400 per QALY gained for the STD clinics, and was
cost-saving for the community clinic, assuming that the HIV
infections detected through NAAT screening would otherwise
have been detected by repeat antibody testing 1 y later (base case,
Table 4). AHI screening would remain cost-saving in the
community clinic, but the cost-effectiveness ratios for the
counseling and testing sites and STD clinics would increase to
approximately US$1 million per QALY gained if these HIV
infections were detected 6 mo later because of more frequent
repeat antibody testing. If repeat antibody testing did not occur
until 5 y later, the cost per QALY gained was cost-saving in all
three settings (Table 4). If HIV infections identified as AHIs were
detected by antibody screening within 3 mo of infection because
of more frequent retesting at the community clinic that serves
MSM population, the cost-effectiveness ratio changed from cost-
saving to a positive incremental cost-effectiveness ratio (ICER) of
US$5,700 per QALY gained.
Cost-Effectiveness of NAAT Screening after Rapid Testing.
The addition of pooled NAAT for detection of AHI after a
negative rapid antibody test had a cost-effectiveness ratio of
US$217,900 per QALY gained for the counseling and testing sites,
US$260,500 per QALY gained for the STD clinics, and was cost-
saving for the community clinic with the base case assumption that
HIV infections detected through NAAT screening would other-
wise have been detected by repeat antibody testing 1 y later. If
HIV infections were detected 6 mo later through repeat antibody
Table 3. Program costs and outcomes of pooled NAAT screening for AHI after third-generation EIA or rapid testing.
Antibody Test Counseling and Testing Sites Community Clinic Municipal STD Clinics
3
rd-Gen EIA Rapid Test 3
rd-Gen EIA Rapid Test 3
rd-Gen EIA Rapid Test
Total program costs, US$ 458,200 459,000 76,900 79,000 349,900 350,500
Number of specimens tested 54,187 54,192 5,574 5,587 30,973 30,977
Cost per specimen tested 8.46 8.47 13.80 14.14 11.30 11.31
AHI cases identified and notified 5.0 8.44 9.69 20.58 3.89 6.86
Program cost per AHI identified and notified, US$ 91,600 54,400 7,900 3,800 90,000 52,000
3
rd-Gen, third-generation.
doi:10.1371/journal.pmed.1000342.t003
Table 4. Costs-effectiveness of pooled NAAT screening for AHI after third-generation EIA and rapid testing.
Antibody Test HIV Counseling and Testing Sites Community Clinic Municipal STD Clinics
3
rd-Gen EIA Rapid Test 3
rd-Gen EIA Rapid Test 3
rd-Gen EIA Rapid Test
Base case: HIV diagnosis 1 y after infection
w/o NAAT
HIV infections averted 0.41 0.51 0.90 1.46 0.32 0.42
HIV treatment costs averted 145,200 181,800 321,700 521,100 113,000 147,800
QALYS gained 2.63 3.29 5.82 9.42 2.04 2.67
Net cost per case averted, US$ 977,400 716,300 (236,700) (467,200) 989,200 695,900
Cost per QALY, US$ 372,300 217,900 Cost-saving Cost-saving 484,400 260,500
HIV diagnosis 6 mo after infection w/o NAAT
HIV infections averted 0.26 0.26 0.60 0.82 0.20 0.21
HIV treatment costs averted 566,800 92,900 1,179,400 293,500 440,900 75,500
QALYS gained 1.67 1.68 3.88 5.30 1.30 1.36
Net cost per case averted, US$ 1,669,300 1,665,200 (86,900) (197,700) 1,657,700 1,651,600
Cost per QALY, US$ 997,900 991,700 Cost-saving Cost-saving 1,274,100 1,154,600
HIV diagnosis 5 y after infection w/o NAAT
HIV infections averted 1.41 2.23 2.95 5.85 1.10 1.81
HIV treatment costs averted 503,600 793,700 1,047,900 2,081,100 391,700 645,200
QALYS gained 9.10 14.35 18.94 37.62 7.08 11.66
Net cost per case averted, US$ (179,800) (610,900) (1,021,800) (2,069,100) (73,800) (473,500)
Cost per QALY, US$ Cost-saving Cost-saving Cost-saving Cost-saving Cost-saving Cost-saving
Cost-saving denotes a cost per QALY value ,0 and is reported as ‘‘cost-saving’’ [16]. Discount rate is 3%.
3
rd-Gen, third-generation.
doi:10.1371/journal.pmed.1000342.t004
Cost-Effectiveness of Pooled NAAT
PLoS Medicine | www.plosmedicine.org 5 September 2010 | Volume 7 | Issue 9 | e1000342testing, AHI screening remained cost-saving in the community
clinic, but the cost-effectiveness ratios would be US$991,700 and
US$1,154,600 per QALY gained for the counseling and testing
sites and municipal STD clinics, respectively. If repeat antibody
testing did not occur until 5 y later, pooled NAAT for AHI
detection was cost-saving in all three settings (Table 4).
Sensitivity Analyses
The results of the threshold analysis on AHI positivity rate can
be found in Figure 1. If AHI positivity is twice as high as observed
in the municipal STD clinics (0.04% compared to 0.02%) with
NAAT screening after third-generation antibody testing, the cost-
effectiveness ratio would fall to US$100,000 per QALY gained.
Additionally, for a given AHI positivity rate, cost-effectiveness
ratios are higher for pooled NAAT after rapid testing compared to
third-generation EIA. At AHI positivity rates of 0.6% or higher,
pooled NAAT after third-generation EIA testing becomes cost-
saving and cost-effective after rapid testing.
Figure 2 shows the results of sensitivity analyses for NAAT
screening after a negative third-generation EIA for municipal STD
clinics under the base case assumption regarding repeat antibody
testing at 1 y. Results are not sensitive to a 25% variation in the
transmission rate ratio for those unaware compared to those aware
of their HIV serostatus for which cost-effectiveness ratios ranged
from US$335,000 to US$855,900 per QALY. Results are also not
sensitive to use of MSM-only transmission rates versus combined
MSM-heterosexual transmission rates, which resulted in cost-
effectiveness ratios above US$200,000 per QALY. Cost-effective-
ness ratios remained well above US$200,000 per QALY when
lifetime medical costs are varied 50%, receipt of results notification
is varied from 50% to 100%, and days to results notification are
varied from 7 to 22 d. However, in two-way sensitivity analysis, the
combination of 100% notification and 7-d receipt of results
resulted in a cost-effectiveness ratio of US$73,500 per QALY
gained. When we varied reagent cost from US$0.00 to US$100.00,
cost-effectiveness ratios ranged from US$188,900 to US$927,700.
Cost-effectiveness ratios remained above US$400,000 when shipp-
ing costs were eliminated. Finally, accounting for symptomatic
detection of AHI increased the cost-effectiveness ratio to over
US$700,000 per QALY gained.
Cost-effective ratios remained cost-saving for the community
clinic that serves an MSM population with a 25% variation in the
transmission rate ratio for those unaware compared to those aware
of their HIV serostatus. Additionally, pooled NAAT with
symptomatic detection of AHI remained cost-saving for the
community clinic (unpublished data).
Discussion
We found that pooled NAAT screening for AHI after a negative
third-generation EIA in clinical settings relevant to public health is
not likely to be cost-effective for most settings. Pooled NAAT
screening for AHI is cost-effective only when targeted to settings
with very high HIV incidence, such as the community clinic,
where it remained cost-effective compared with retesting for HIV
antibody as often as every 3 mo. At US$370,000–US$1 million per
QALY gained in counseling and testing sites and STD clinics,
pooled NAAT after a negative third-generation EIA was not
within acceptable ranges of cost-effectiveness thresholds of
US$100,000–US$200,000 per QALY gained [33,34] unless
high-risk persons were retested very infrequently. When we
assessed the use of pooled NAAT to detect AHI after negative
rapid HIV tests, which are less sensitive during early infection than
Figure 1. Sensitivity analysis: relationship between AHI positivity rate and cost per QALY gained. Rounded to the nearest tenth of a
percentage point. 3
rd-Gen EIA, third-generation enzyme immunoassay.
doi:10.1371/journal.pmed.1000342.g001
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the same.
Our findings were most sensitive to AHI positivity rate and
assumptions about frequency of antibody testing among infected
persons. For the municipal STD clinics to fall within the range of
threshold values for cost-effectiveness, the AHI positivity rate
would need to nearly double to 0.04% from 0.02%. Our analysis is
heavily influenced by the transmission rate ratio of those who are
aware versus unaware of their status. However, our findings were
not sensitive to a 25% variation in this parameter. When we
accounted for symptomatic detection of AHI outside the screening
program, AHI screening with pooled NAAT became much less
cost-effective for the municipal STD clinics. Thus symptomatic
detection of AHI cases can be an important consideration in
pooled NAAT for AHI detection in clinical settings. In one AHI
screening program, 60% of persons tested were symptomatic and
providers suspected AHI in 48% of symptomatic cases [14].
In the base case scenario, we assumed testing at yearly intervals
because all settings evaluated in our analysis serve high-risk
populations for whom testing is recommended at least annually
[24]. However, if retesting is infrequent and HIV infection is not
identified until 5 y after infection, the benefits from the infections
averted by NAAT screening that accrue over this period make
NAAT screening cost-saving in all settings we evaluated. Notably,
most of the benefits that make NAAT screening cost-effective
during a 5-y interval between retesting occur long after the acute
phase, when antibody testing could have been repeated. When we
narrowed the testing interval to 6 mo, NAAT was not cost-
effective in any setting except the community clinic, and in this
setting, it was cost-effective even at a 3-mo testing interval. Recent
reports advocate the use of NAAT in high-incidence groups that
undergo testing frequently [8]. High testing frequency (e.g., every
6 mo) has been observed among risk groups with the highest
incidence of HIV infection, and gay-identified men with AHI
typically have been tested in the year before diagnosis [8,15,35].
However, we found that the relative benefits of reduced HIV
transmission due to NAAT generally diminish as the frequency of
antibody testing increases.
The small number of persons with AHI identified by NAAT
and the large number of specimens that need to be tested to find
them appear to drive our results. Furthermore, approximately
25% of persons with AHI did not receive their test results, and
those who did were notified well into the acute phase, on average
on days 32 and 48 of the 49-d acute infection period with third-
generation EIA screening and rapid testing, respectively. While
pooled NAAT detected HIV infection in antibody-negative
persons, it did not result in persons learning of their infection
early enough to reduce the potential for transmission during the
infectious AHI period as much as was expected, which limited the
public health benefit of NAAT screening. Timely testing and
Figure 2. Tornado diagram of sensitivity analysis results. Based on municipal STD clinic data after third-generation EIA assuming a 1-y
antibody retesting interval. Base case value = US$484,400 per QALY gained.
doi:10.1371/journal.pmed.1000342.g002
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of AHI screening are to be optimized and are important
considerations for implementing NAAT in real-world settings. If
receipt of results dropped to 50% or results notification takes 22 d
rather then 15 d, the cost-effectiveness greatly exceeds
US$500,000 per QALY. Pooled NAAT screening was cost-
effective in sensitivity analysis with 100% notification and 7-d
receipt of results. However, it is unclear how feasible 7-d
notification of NAAT results is; in another AHI screening
program, time to results notification following AHI screening
was similar or slightly longer than that reported in the CDC AHI
study [14]. Alternate methods for delivering NAAT results such as
the internet and telephone might be considered to increase the
proportion of persons who receive their NAAT results.
AHI positivity rates in a given population are generally higher
with pooled NAAT after rapid testing compared to third-
generation EIA screening due to the lower sensitivity of the rapid
test during the first few weeks after infection. However, these
additional cases might be identified much later in the acute phase
because of the longer antibody-negative window period, poten-
tially diminishing some of the reductions in acute phase
transmissions, which, in our analysis, made pooled NAAT after
rapid testing less cost-effective than pooled NAAT after third-
generation EIA screening at similar AHI positivity rates.
Although high infectivity during AHI has been a prime reason
to advocate for NAAT screening to detect AHI, our sensitivity
analysis suggests that even notifying persons with AHI of their test
results within 7 d after screening (which would reduce the interval
during which persons with AHI might transmit HIV by 8.5 d)
would still result in cost-effectiveness ratios beyond generally
accepted threshold values. Larger pool sizes have been suggested
as a way to increase AHI screening efficiency and decrease costs.
The CDC AHI study was able to retrospectively detect most cases
of AHI when retesting samples using a 128-member, two-stage
pooling scheme, compared to the original pool size of 16
suggesting an intermediate pool size between 16 and 128 members
[36,37]. It is unlikely, however, that the larger pool size would be
more cost-effective because we reduced reagent costs to zero in
sensitivity analysis and the cost-effective ratio was still close to
US$200,000 per QALY. Additionally, larger pool sizes could
increase turn-around time, which will reduce or eliminate the
benefit of awareness during the acute phase and may be more
costly due to higher reagent costs for resolution testing of larger
pools. Smaller pool sizes may decrease turn around time, but
reducing time to receipt of NAAT results to 7 d, less than half of
the base case value, still resulted in cost-effectiveness ratios in
excess of US$350,000 per QALY.
While routine HIV screening has been found to be cost-effective
[38], NAAT has been found to be well outside the range of cost-
effectiveness at US$7–US$9 million per QALY gained when
evaluated in the context of volunteer blood donation screening for
HIV [39,40]. We believe our study to be the first micro-costing
study of pooled NAAT in clinical settings. Our analysis includes a
detailed valuation of labor costs associated with NAAT screening,
and shipping costs, which accounted for 20% of total costs in our
study and are likely to play a continuing role in any NAAT
screening program because of the need for pooled testing at a
regional, high-complexity laboratory.
Our study clearly illustrates that NAAT screening for AHI
should be reserved for settings that serve the highest-incidence
populations, or circumstances such as donor screening where cost-
effectiveness is not a primary consideration [41,42]. The challenge
for public health providers will be to determine how to identify
such settings and improve the yield of NAAT screening [9]. HIV
positivity and AHI screening yield are not necessarily correlated
[15]. Thus, other metrics are needed to identify settings in which
AHI screening is likely to be cost-effective. Similar analyses will
need to be conducted with alternatives to pooled NAAT such as
fourth-generation EIA. Fourth-generation EIA detects both HIV
antibody and p24 antigen in a single screening test and can be
almost as effective as NAAT in identifying AHI with a potentially
shorter turnaround time for results [10,15].
Our study is subject to several limitations. Our analysis is based
on a clinical trial of NAAT conducted in three types of settings
with different HIV positivity rates. Caution should be used in
applying these results to similar settings because of limited
information on the correlation between AHI and HIV positivity
rates and the relationship of these factors to the prevalence of risk
behavior. Although we assessed the costs of false-positive NAAT
results, we did not include any quality-of-life adjustments.
However, there were only two false positive NAAT tests out of
90,834 specimens screened in this study [15]. We assumed that
awareness of AHI would be associated with the same degree of
behavior change as has been estimated for awareness of nonacute
HIV infection, but data are not yet available to confirm this
assumption. Like many other HIV screening cost-effectiveness
analyses, calculation of transmissions averted in our study include
only first-generation transmissions, which underestimates the total
number of infections attributable to each AHI case [39,43].
Additionally, our transmission model uses the same transmission
rates for heterosexuals and MSM, thus our estimates are slightly
conservative with regard to MSM populations, though our
findings did not change when MSM only transmission rates were
used in sensitivity analysis. We did, however, account for variation
in transmission risk by stage of infection, which has not typically
been done in other cost-effectiveness analyses of HIV screening.
We are also limited by possible changes in costs and effectiveness
of ART given that persons with AHI will not be treated for several
years. We addressed this in sensitivity analysis using a 50%
variation in ART costs, which did not appreciably change the cost-
effectiveness ratios. Finally, we did not include benefits related to
earlier linkage to care due to pooled NAAT; however, this will
need to be reevaluated if treatment becomes recommended during
acute and early HIV infection.
Conclusions
Pooled NAAT screening for AHI after negative third-genera-
tion EIA or rapid tests is not cost-effective when antibody testing
frequency is at recommended levels for high-risk populations
except in very high-incidence settings. When antibody testing
frequency is 5 y or greater, pooled NAAT screening is cost-saving;
however, most of the benefits achieved occur long after the acute
phase and could have been achieved with antibody testing alone.
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Background. Since 1981, acquired immunodeficiency
syndrome (AIDS) has killed about 25 million people and
about 30 million people are now infected with the human
immunodeficiency virus (HIV), which causes AIDS. HIV, which
is most often transmitted through unprotected sex with an
infected partner or injection drug use, infects and kills
immune system cells, leaving infected individuals susceptible
to other infectious diseases. The first, often undiagnosed
stage of HIV infection—acute HIV infection (AHI)—lasts a few
weeks and sometimes involves a flu-like illness. During AHI,
the immune system responds to HIV by beginning to make
antibodies that recognize the virus but seroconversion—the
appearance of detectable amounts of antibody in the
blood—takes 6–12 weeks. During the second, symptom-
free stage of HIV infection, which can last many years, the
virus gradually destroys the immune system so that by the
third stage of infection unusual infections (for example,
persistent yeast infections) begin to occur. The final stage of
infection (AIDS) is characterized by multiple severe infections
and by the development of unusual cancers.
Why Was This Study Done? Antiretroviral drugs control
HIV infections but don’t cure them. It is very important,
therefore, to prevent HIV transmission by avoiding HIV risk
behaviors that increase the risk of HIV infection such as
having sex without a condom or with many partners.
Individuals with AHI in particular need to avoid high-risk
behaviors because these people are extremely infectious.
However, routine tests for HIV infection that measure
antibodies in the blood often give false-negative results in
people with AHI because of the time lag between infection
and seroconversion. Nucleic acid amplification testing
(NAAT), which detects HIV genetic material in the blood, is
a more accurate way to diagnose AHI but is expensive. In this
study, the researchers investigate whether pooled NAAT
screening (specimens are pooled before testing to reduce
costs) for AHI in clinic settings after third-generation
antibody testing is a cost-effective HIV prevention strategy.
That is, does the gain in quality-adjusted life years (QALY, a
measure of the quantity and quality of life generated by
healthcare interventions) achieved by averting new HIV
infections outweigh the costs of pooled NAAT screening?
What Did the Researchers Do and Find? Theresearchers
combined effectiveness data from a US study in which AHI
was detected using pooled NAAT in three settings (sexually
transmitted disease [STD] clinics, a community clinic serving
men who have sex with men [MSM], and HIV counseling/
testing sites) with a ‘‘micro-costing’’ study of NAAT and a
mathematicalmodelofHIVtransmission.They thencalculated
the costs per QALY gained (the cost-effectiveness ratio) as a
result of HIV prevention by identification and notification of
people with AHI through pooled NAAT screening compared
with repeat antibody testing. Pooled NAAT for AHI screening
following annual antibody testing (the recommended testing
interval for high-risk individuals), they estimate, would cost
US$372,300 and US$484,400 per QALY gained for the
counseling/testing sites and STD clinics, respectively, where-
as pooled NAAT for AHI screening was cost-saving for the
community clinic serving MSM. The cost-effectiveness ratio
increased for the counseling/testing sites and STD clinics
when the antibody testing interval was decreased to 6
months but remained cost-saving for the community clinic.
With an antibody testing interval of 5 years, pooled NAAT was
cost-saving in all three settings.
What Do These Findings Mean? Cost-effectiveness ratios
of US$100,000–US$200,000 are considered acceptable in the
US. These results suggest therefore, that the cost of pooled
NAAT screening for AHI following negative third-generation
antibody testing is not acceptable at the recommended
testing interval for high-risk individuals except in settings
where HIV infection is very common such as clinics serving
MSM. The researchers reach a similar conclusion in a separate
cost-effectiveness analysis of pooled NAAT screening
following a negative rapid HIV test. Although the accuracy
of these results depends on numerous assumptions made in
the cost-effectiveness analyses (for example, the degree to
which awareness of HIV status affects the behavior of people
with AHI), sensitivity analyses (investigations of the effect of
altering key assumptions) show that these findings are not
greatly affected by changes in many of these assumptions.
Thus, the researchers conclude, NAAT screening should be
reserved for settings that serve populations in which there
are very high levels of new HIV infection.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000342.
N The US Centers for Disease Control and Prevention
provides information on HIV infection and AIDS and on
HIV testing and diagnosis
N HIV InSite has information on all aspects of HIV/AIDS
N Information is available from Avert, an international AIDS
nonprofit organization on many aspects of HIV/AIDS,
including HIV testing (in English and Spanish)
N MedlinePlus has links to further resources on AIDS (in
English and Spanish)
N The UK National Institute of Health and Clinical Excellence
has a page on measuring effectiveness and cost-effective-
ness
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